Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial

Jean-Louis A Ndiaye, Babacar Faye, Ali Gueye, Roger Tine, Daouda Ndiaye, Corinne Tchania, Ibrahima Ndiaye, Aichatou Barry, Badara Cissé, Valérie Lameyre, Oumar Gaye, Jean-Louis A Ndiaye, Babacar Faye, Ali Gueye, Roger Tine, Daouda Ndiaye, Corinne Tchania, Ibrahima Ndiaye, Aichatou Barry, Badara Cissé, Valérie Lameyre, Oumar Gaye

Abstract

Background: The use of artemisinin-based combination therapy (ACT) is currently recommended for treating uncomplicated malaria. The objective was to assess the efficacy and safety of repeated administrations of two fixed-dose presentations of ACT--artesunate plus amodiaquine (ASAQ) and artemether-lumefantrine (AL)--in subsequent episodes of Plasmodium falciparum malaria.

Methods: A randomized comparative study was conducted in a rural community of central Senegal from August 2007 to January 2009. Children and adults with uncomplicated P. falciparum malaria were randomized to receive open-label ASAQ once daily or AL twice daily for three days. Drug doses were given according to body weight. Treatments for first episodes were supervised. For subsequent episodes, only the first intake of study drug was supervised. ECGs and audiograms were performed in patients ≥ 12 years of age. Primary outcome was adequate clinical and parasitological response rate (ACPR) after polymerase chain reaction (PCR) correction on day 28 for the first episode.

Results: A total of 366 patients were enrolled in the two groups (ASAQ 184, AL 182) and followed up during two malaria transmission seasons. In the intent-to-treat population, PCR-corrected ACPRs at day 28 for the first episode were 98.4% and 96.2%, respectively, in the ASAQ and AL groups. For the per-protocol population (ASAQ 183, AL 182), PCR-corrected ACPRs at day 28 for the first episode were 98.9% and 96.7%, respectively. A 100% ACPR rate was obtained at day 28 in the 60 and four patients, respectively, who experienced second and third episodes. Treatment-related adverse events were reported in 11.7% of the patients, without significant differences between the two groups. A better improvement of haemoglobin at day 28 was noted in the ASAQ versus the AL group (12.2 versus 11.8 g/dL; p = 0.03). No sign of ototoxicity was demonstrated. A prolongation of the QTc interval was observed in both groups during treatment with no clinical consequence.

Conclusions: Study results confirmed the satisfactory efficacy and safety profile of ASAQ and AL. Moreover, in patients who were treated at least twice, repeated administration of ASAQ or AL did not identify any major safety issues.

Trial registration: ClinicalTrials.gov identifier NCT00540410.

Figures

Figure 1
Figure 1
Disposition of patients according to the number of malarial episodes experienced in a randomized open-label study: comparing treatment with fixed-dose combinations of artesunate plus amodiaquine (ASAQ) and artemether plus lumefantrine (AL).
Figure 2
Figure 2
Effects of 3 days' treatment with fixed dose combination of artesunate plus amodiaquine (ASAQ) or artemether plus lumefantrine (AL) started on day 0 of the first episode of malaria on the rate of parasite clearance.
Figure 3
Figure 3
Blood haemoglobin levels following treatment with a fixed-dose combination of artesunate plus amodiaquine (ASAQ) or artemether plus lumefantrine (AL) for the first malaria episode in the intent-to-treat population.
Figure 4
Figure 4
QTcF at day 0 and day 3 after treatment with a fixed-dose combination of artesunate plus amodiaquine (ASAQ) or artemether plus lumefantrine (AL) for the first malaria episode in the intent-to-treat population.

References

    1. World Health Organization. Fact sheet: malaria No. 94 WHO, Geneva 2010.
    1. Roll Back Malaria Partnership. Roll Back Malaria. Progress and impact series: focus on Senegal.
    1. World Health Organization. Antimalarial drug combination therapy: Report of a WHO Technical Consultation. WHO Press: Geneva; 2001.
    1. World Health Organization. Guidelines for the treatment of malaria. WHO Press: Geneva; 2006.
    1. World Health Organization. Guidelines for the treatment of malaria. Second. WHO Press, Geneva; 2010.
    1. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today. 1996;12:399–401. doi: 10.1016/0169-4758(96)10055-7.
    1. Price RN, Nosten F, Luxemburger C, terKuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 1996;347:1654–1658. doi: 10.1016/S0140-6736(96)91488-9.
    1. Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WR, Olliaro P. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Malar J. 2007;6:150. doi: 10.1186/1475-2875-6-150.
    1. Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malar J. 2007;6:80. doi: 10.1186/1475-2875-6-80.
    1. Tall A, Rabarijaona LP, Robert V, Bedja SA, Ariey F, Randrianarivelojosia M. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union. Acta Trop. 2007;102:176–181. doi: 10.1016/j.actatropica.2007.03.004.
    1. Fofana B, Djimde A, Sidibe B, Dembele D, Toure S, Lameyre VV. Comparative efficacy, safety and tolerability of three treatment regimens for uncomplicated falciparum malaria: artesunate (3 days) + amodiaquine (3 days) vs. amodiaquine (3 days) vs. artesunate (3 days) vs. sulfadoxine-pyrimethamine (1 day) vs. artesunate (5 days) Am J Trop Med Hyg. 2004;17(4 Suppl):26.
    1. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O. Randomized, multicentre assessment of the efficacy and safety of ASAQ - a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J. 2009;8:125. doi: 10.1186/1475-2875-8-125.
    1. Sirima SB, Tiono AB, Gansané A, Diarra A, Ouédraogo A, Konaté AT, Kiechel JR, Morgan CC, Olliaro PL, Taylor WR. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young children with acute uncomplicated Plasmodium falciparum. Malar J. 2009;8:48. doi: 10.1186/1475-2875-8-48.
    1. Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, Cohuet S, D'Alessandro U, Djimdé A, Karema C, Guthmann JP, Hamour S, Ndiaye JL, Mårtensson A, Rwagacondo C, Sagara I, Same-Ekobo A, Sirima SB, van den Broek I, Yeka A, Taylor WR, Dorsey G, Randrianarivelojosia M. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203. doi: 10.1186/1475-2875-8-203.
    1. Souares A, Lalou R, Sene I, Sow D, Le Hesran JY. Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in rural Senegal. Trans R Soc Trop Med Hyg. 2008;102:751–758. doi: 10.1016/j.trstmh.2008.05.016.
    1. Djimdé A, Doumbo OK, Cortese JF, Kassoum K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:299–302. doi: 10.1056/NEJM200101253440411.
    1. Foley M, Ranford-Cartwright LC, Babiker HA. Rapid and simple method for isolating malaria DNA from fingerprick samples of blood. Mol Biochem Parasitol. 1992;53:241–244. doi: 10.1016/0166-6851(92)90026-G.
    1. World Health Organization. Evaluation et surveillance de l'efficacité des antipaludiques pour le traitement du paludisme à Plasmodium falciparum non compliqué. Geneva. 2003.
    1. Mutabingwa TK, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood B, Whitty CJ. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474–1480. doi: 10.1016/S0140-6736(05)66417-3.
    1. Brasseur P. Tolerance of amodiaquine. Med Trop. 2007;67:288–290.
    1. Edwards IR. Safety monitoring of new anti-malarials in immediate post-marketing phase. Med Trop. 1998;58(3 Suppl):93–96.
    1. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, Sutherland C, Sauerwein R, Ghani AC, Drakeley C. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010;24:136.
    1. Ouédraogo AL, Bousema T, Schneider P, de Vlas SJ, Ilboudo-Sanogo E, Cuzin-Ouattara N, Nébié I, Roeffen W, Verhave JP, Luty AJ, Sauerwein R. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS ONE. 2009;4:e8410. doi: 10.1371/journal.pone.0008410.
    1. Matsui D. Current issues in pediatric medication adherence. Paediatr Drugs. 2007;9:283–288. doi: 10.2165/00148581-200709050-00001.
    1. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J. 2006;5:50. doi: 10.1186/1475-2875-5-50.
    1. Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, Talisuna AO, Staedke SG. Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health. 2008;13:1143–1152. doi: 10.1111/j.1365-3156.2008.02119.x.
    1. National Malaria Control Programme 2007. Annual report of pharmacovigilance. NMCP: Dakar; 2008.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren